

## HR 6839

To direct the Comptroller General of the United States to submit a report describing the response of certain entities to the COVID-19 pandemic with respect to the development, regulatory evaluation, and deployment of diagnostic tests.

**Congress:** 116 (2019–2021, Ended)

**Chamber:** House

**Policy Area:** Health

**Introduced:** May 12, 2020

**Current Status:** Referred to the House Committee on Energy and Commerce.

**Latest Action:** Referred to the House Committee on Energy and Commerce. (May 12, 2020)

**Official Text:** <https://www.congress.gov/bill/116th-congress/house-bill/6839>

### Sponsor

**Name:** Rep. Spanberger, Abigail Davis [D-VA-7]

**Party:** Democratic • **State:** VA • **Chamber:** House

### Cosponsors (1 total)

Cosponsor	Party / State	Role	Date Joined
Rep. Gonzalez, Anthony [R-OH-16]	R · OH		May 12, 2020

### Committee Activity

Committee	Chamber	Activity	Date
Energy and Commerce Committee	House	Referred To	May 12, 2020

### Subjects & Policy Tags

**Policy Area:**

Health

### Related Bills

Bill	Relationship	Last Action
116 HR 6800	Related bill	Jul 23, 2020: Committee on Small Business and Entrepreneurship. Hearings held. Hearings printed: S.Hrg. 116-517.

### Summary (as of May 12, 2020)

This bill requires the Government Accountability Office (GAO) to report on diagnostic tests to diagnose COVID-19 (i.e., coronavirus disease 2019) or detect the virus that causes the disease. Specifically, the report must describe the response of, among others, laboratories, diagnostic test manufacturers, and government entities with respect to the development, regulatory evaluation, and deployment of diagnostic tests. The GAO must also assess standards, guidance, clinical processes, and intergovernmental coordination related to COVID-19 testing.

## **Actions Timeline**

---

- **May 12, 2020:** Introduced in House
- **May 12, 2020:** Referred to the House Committee on Energy and Commerce.